Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Debiopharm

- PMLiVE

Merck abandons evofosfamide as two trials fail

Solid tumour candidate underwhelms in phase III studies

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Merck appoints new senior vice president

Laszlo Radvanyi joinsthe firm

- PMLiVE

Merck names new CEO and rebrands under one name

New logo and appointment of Stefan Oschmann from next year

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Merck takes novel immuno-oncology drug into clinical trials

Potential to offer alternative to anti-PD-1/anti-PDL1 immunotherapies 

- PMLiVE

Merck KGaA appoints Isabel De Paoli as communications head

She will replace Walter Huber, who retires inMarch 2016

- PMLiVE

A bright future for OTC and Merck Consumer Health

It’s an exciting time for the OTC sector. Consumers have never been more interested in wellbeing and, of course, avoiding illness. This is driving change, and quickly. The market is...

- PMLiVE

2015 set to be a transitional year for Merck KGaA’s health unit

Weak pharma sales reported by the firm today

- PMLiVE

Merck KGaA, Threshold gain FDA fast-track review

Industry partners hope their new cancer drug will be approved by the end of the year

- PMLiVE

Merck KGaA ‘to promote’ Stefan Oschmann to chief executive

Germanphamra company reportedly set to elevate him to the top job next year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links